Condizione: acceptable. Fairly worn, but readable and intact. If applicable: Dust jacket, disc or access code may not be included.
paperback. Condizione: Very Good. The copy shows minor external wear, but is in otherwise clean condition.
Lingua: Inglese
Editore: Springer Publishing Co Inc, New York, 2025
ISBN 10: 0826184413 ISBN 13: 9780826184412
Da: Grand Eagle Retail, Bensenville, IL, U.S.A.
Paperback. Condizione: new. Paperback. Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options.With over 35 new FDA-approved indications since the second editionfeaturing groundbreaking advancements such as CAR-T therapythis handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers.Key Features:New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.Entirely new board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
EUR 100,05
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
EUR 102,81
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
EUR 105,08
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
EUR 137,37
Quantità: 2 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. 3rd new edition. 660 pages. 8.00x5.00x8.00 inches. In Stock.
Lingua: Inglese
Editore: Springer Publishing Co Inc, New York, 2025
ISBN 10: 0826184413 ISBN 13: 9780826184412
Da: CitiRetail, Stevenage, Regno Unito
EUR 149,76
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: new. Paperback. Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options.With over 35 new FDA-approved indications since the second editionfeaturing groundbreaking advancements such as CAR-T therapythis handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers.Key Features:New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.Entirely new board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
Lingua: Inglese
Editore: Springer Publishing Jun 2025, 2025
ISBN 10: 0826184413 ISBN 13: 9780826184412
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 142,69
Quantità: 2 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware - Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options.With over 35 new FDA-approved indications since the second edition-featuring groundbreaking advancements such as CAR-T therapy-this handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers.Key Features:- New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.- Entirely new board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.- Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.- Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.- Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.
Lingua: Inglese
Editore: Springer Publishing Co Inc, New York, 2025
ISBN 10: 0826184413 ISBN 13: 9780826184412
Da: AussieBookSeller, Truganina, VIC, Australia
EUR 177,32
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: new. Paperback. Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options.With over 35 new FDA-approved indications since the second editionfeaturing groundbreaking advancements such as CAR-T therapythis handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers.Key Features:New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.Entirely new board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.